Sharekhan's research report on Gland Pharma
Gland reported healthy results for Q4FY22 with the revenues staging a strong double digit growth while PAT staged a 9.8% yoy growth. Gland has lined up a strong new launch pipeline in the us markets comprising 20-25 new launches over the next three quarters offering addressable market size of $3bn. Gland has repurposed its Vaccine manufacturing facility to a biosimilar CDMO and is awaiting customer visits over the near to medium term.
Outlook
We maintain Buy on the stock of Gland Pharma with a revised PT of Rs 3770. Strong domain expertise and growth prospects, sturdy earnings track record, and strong financials are key positives for Gland.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Read More